Insider Activity
$184.7K buy / $0.00 sell
ED
EDAP
EDAP TMS SA
—
12-mo target$5.83 (+35.0%)
Insider Buying Cluster (4 insiders) Healthcare & Medical Devices
Snapshot
The big-picture read on EDAP right now — valuation, ownership and activity at a glance.
Insider Net $
$184.7K
SEC Reports
9
Press Releases
3
Price chart
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 18, 2026 SEC May 14, 2026 Press
Four insiders, including CFO Kenneth Mobeck, SVP Steven Annen, and directors Joshua Levine and David Horn, purchased a t
CLUSTER — Impact 5/10
Aug 14, 2026 Insider
Horn David R. bought 10,000 shares
Director @ $4.75 ($47.5K)
Aug 14, 2026 Insider
Annen Steven bought 5,000 shares
SVP, Marketing & Product Mgmt. @ $4.75 ($23.8K)
Aug 14, 2026 Insider
May 29, 2026 SEC Mobeck Kenneth S. bought 5,000 shares
Chief Financial Officer @ $4.75 ($23.8K)
EDAP TMS SA announced it will operate under the new corporate name 'FocalTherics' and change its Nasdaq ticker to 'FOCL'
8-K — Impact 4/10
May 29, 2026 other
May 14, 2026 SEC EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics ™ to Reflect
EDAP TMS SA filed its management report for the 2025 fiscal year ahead of the June 26, 2026 annual general meeting. Cons
DEFA14A — Impact 6/10
EDAP TMS announced a non-binding letter of intent with Telix Pharmaceuticals to explore joint clinical research and phys
Impact 3/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Apr 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Apr 4, 2025 | Jefferies | DOWNGRADE | Hold | 53% |
| Mar 28, 2025 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Mar 28, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 29, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jul 22, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 17, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Apr 1, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Nov 10, 2023 | Piper Sandler | MAINTAIN | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Apr 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Mar 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Feb 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Jan 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% |
Price targets
Where 3 covering analysts think EDAP trades over the next 12 months.
$5.83 +35.0% upside Strong Buy
Current$4.32 Low$3.00 Median$4.50 High$10.00 3 analysts
$3.00$10.00
Analyst rating None as of Aug 8, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 0 bullish, 1 bearish, 2 mixed, 6 neutral · avg impact 4.4/10.Plus 3 press releases.
MIXEDCLUSTER5/10
Four insiders, including CFO Kenneth Mobeck, SVP Steven Annen, and directors Joshua Levine and David
Aug 18, 2026
NEUTRAL8-K4/10
EDAP TMS SA announced it will operate under the new corporate name 'FocalTherics' and change its Nas
May 29, 2026
BEARISHDEFA14A6/10
EDAP TMS SA filed its management report for the 2025 fiscal year ahead of the June 26, 2026 annual g
May 14, 2026
NEUTRALDEFA14A3/10
EDAP TMS SA filed a DEFA14A providing notice of its 2026 Ordinary and Extraordinary General Meeting
May 14, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
May 29, 2026
other
EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy
, May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics ™ to Reflect Exclusive Focus o
May 21, 2026
other
EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
May 14, 2026
contract
EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer
, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a
May 13, 2026
other
EDAP | Focal One to Host Investor Day on June 1, 2026
, May 13, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Host Investor Day on June 1, 2026
May 7, 2026
earnings
EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue
, May 07, 2026 (GLOBE NEWSWIRE) -- <img height="45.46px" name="GNW_RichHtml_IMG" src="https://ml-eu.globenewswire.com/Resource/Download/396d05d0-
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.20 | $-0.24–$-0.17 | -17.7% | +6.8% | — | $0.0B | 2 |
| Next FY | $-0.59 | $-0.64–$-0.54 | 28.1% | +0.2% | 0↑ 1↓ | $0.1B | 2 |
| Current FY | $-0.82 | $-0.86–$-0.78 | -2.6% | +1.2% | — | $0.1B | 2 |
| Next Q | $-0.23 | $-0.23–$-0.22 | -50.0% | -2.3% | — | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.205 | — |
| 7d ago | $-0.190 | -0.015 |
| 30d ago | $-0.220 | +0.015 |
| 60d ago | $-0.170 | -0.035 |
| 90d ago | $-0.170 | -0.035 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
7 insiders, 14 transactions. Net $184.7K — $184.7K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Horn David R. | Director | BUY | 10,000 | $4.75 | $47.5K |
| Aug 14, 2026 | Annen Steven | SVP, Marketing & Product Mgmt. | BUY | 5,000 | $4.75 | $23.8K |
| Aug 14, 2026 | Mobeck Kenneth S. | Chief Financial Officer | BUY | 5,000 | $4.75 | $23.8K |
| Aug 14, 2026 | LEVINE JOSHUA | Director | BUY | 10,000 | $4.75 | $47.5K |
| May 12, 2026 | Mobeck Kenneth S. | Chief Financial Officer | AWARD | 120,000 | — | — |
| May 12, 2026 | Mobeck Kenneth S. | Chief Financial Officer | AWARD | 144,141 | — | — |
| May 12, 2026 | Shah Sanket | Gen Counsel & Corp Secretary | AWARD | 67,500 | — | — |
| May 12, 2026 | Shah Sanket | Gen Counsel & Corp Secretary | AWARD | 75,000 | — | — |
| May 12, 2026 | WILLSEY LANCE | Director | AWARD | 114,285 | — | — |
| May 12, 2026 | Rhodes Ryan | Chief Executive Officer | AWARD | 304,500 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for EDAP.
Shares short
56,059
Settlement May 29, 2026
Change vs prior
-1.7%
Semi-monthly cycle
Days to cover
1.6
At avg daily volume
All EDAP filing & press-release reports (12)
- CLUSTER reportAug 18, 2026
- 8-K reportMay 29, 2026
- DEFA14A reportMay 14, 2026
- DEFA14A reportMay 14, 2026
- PRESS-RELEASE reportMay 14, 2026
- 8-K reportMay 7, 2026
- PRESS-RELEASE reportApr 16, 2026
- EFFECT reportApr 1, 2026
- S-3/A reportMar 27, 2026
- S-3 reportMar 25, 2026
- PRESS-RELEASE reportMar 25, 2026
- PRESS-RELEASE reportMar 4, 2026